Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 635-643

  Crawford, Keith W ^a,b   Spritzler, John ^c   Kalayjian, Robert C ^d   Parsons, Teresa ^a   Landay, Alan ^e   Pollard, Richard ^f   Stocker, Vicki ^g   Lederman, Michael M ^h   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NEPHROTOXICITY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGE; CHEMISTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PLASMA; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PLASMA; PYRIMIDINONES; YOUNG ADULT;

EID: 77954206288     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0154     Document Type: Article

References (79)

1. Murphy EL, Collier AC, Kalish LA, et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135(1):17-26.
2. McDavid K, Li J, and Lee LM: Racial and ethnic disparities in HIV diagnoses for women in the United States. J Acquir Immune Defic Syndr 2006;42(1):101-107.
3. HIV=AIDS Surveillance Report: HIV infection and AIDS in the United States, 2004. Centers for Disease Control and Prevention, Atlanta, GA.
4. New Estimates of U.S. HIV Prevalence, 2006: Centers for Disease Control and Prevention, Atlanta, GA, October 2008.
5. Hall HI, McDavid K, Ling Q, and Sloggett A: Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol 2006;16(11):824-833.
6. Porter K, Babiker A, Bhaskaran K, et al.: Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362(9392):1267-1274.
7. Egger M, May M, Chêne G, Phillips AN, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360(9327):119-129. Erratum in Lancet 2002; 360(9340):1178. (Pubitemid 34786200)
8. Kitahata MM, Gange SJ, Abraham AG, et al.: Effect of Early versus deferred antiretroviral therapy for HIV on Survival. N Engl J Med 2009;360:1815-1826.
9. Gruver AL, Hudson LL, and Sempowski GD: Immunosenescence of ageing. J Pathol 2007;211(2):144-156.
10. Tarazona R, Solana R, Ouyang Q, and Pawelec G: Basic biology and clinical impact of immunosenescence. Exp Gerontol 2002;37(2-3):183-189.
11. van Baarle D, Tsegaye A, Miedema F, and Akbar A: Significance of senescence for virus-specific memory T cell responses: Rapid ageing during chronic stimulation of the immune system. Immunol Lett 2005;97(1):19-29.
12. Geskus RB, Meyer L, Hubert JB, and Schuitemaker H: Causal pathways of the effects of age and the CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on AIDS development. J Acquir Immune Defic Syndr 2005;39(3):321-326.
13. Bonnet F, Thiébaut R, Chêne G, et al.: Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 2005;6(3):198-205.
14. Chow KY, Ang LW, Verghesse I, et al.: Measurable predictive factors for progression to AIDS among HIV-infected patients in Singapore. Ann Acad Med Singapore 2005;34(1): 84-89.
15. Touloumi G, Pantazis N, and Babiker AG: Differences in HIV RNA concentrations before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004;18(12):1697-1705.
16. Cusack BJ: Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004;2(4):274-302.
17. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, and Soriano V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27(5):426-431.
18. Schwenk A, Breuer JP, Kremer G, et al.: Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res 2000;5(10):443-448.
19. Luther VP and Wilkin AM: HIV infection in older adults. Clin Geriatr Med 2007;23(3):567-583.
20. Meraviglia P, Schiavini M, and Castagna A: Lopinavir= ritonavir treatment in HIV antiretroviral-experienced patients: Evaluation of risk factors for liver enzyme elevation. HIV Med 2004;5(5):334-343.
21. Kalayjian RC, Spritzler J, Pu M, et al.: Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005;192(9):1577-1587.
22. http:==rcc.tech-res.com=DAIDS%20RCC%20FORMS=Toxicity Tables-HVTN-18sep02- updated.pdf.
23. Lamotte C , Peytavin G , and Farinotti R: Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B 1999;735:159-170.
24. Wei LJ and Johnson WE: Combining dependent tests with incomplete repeated measurements. Biometrika 1985;72(2): 359-364.
25. Xu X, Tian I, and Wei LJ: Combining dependent tests for linkage or association across multiple phenotypic traits. Biostatistics 2003;4(2):223-229.
26. Davidian M and Giltinan DM: Nonlinear Models for Repeated Measurement Data. Chapman & Hall, New York, 1995, Section 9.3.
27. Bertz R, et al.: Steady-state pharmacokinetics of Kaletra (lopinavir=ritonavir 400=100mg BID) in HIV-infected subjects when taken with food. 2nd International Workshop on Clinical Pharmacology of HIV Therapy, April 2-4, 2001, The Netherlands.
28. Abbott Laboratories: Ref: 03-5395-R11. Revised: November, 2004.
29. Crommentuyn KLM, Kappelhoff BS, Mulder JW, et al.: Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-infected patients. Br J Clin Pharm 2005; 60(4):378-389.
30. Kapellhoff BS, et al.: Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol 2004;59:174-182.
31. Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negredo E, Costa J, Domingo P, Clotet B, and Valle M: Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet 2008;47(10):681-692.
32. Kongkaew C, Noyce PR, and Ashcroft DM: Hospital admissions associated with adverse drug reactions: A systematic review of prospective observational studies. Ann Pharmacother 2008;42(7):1017-1025.
33. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al.: Adverse drug reaction-related hospitalisations: A nationwide study in The Netherlands. Drug Saf 2006;29(2): 161-168.
34. van der Leur MR, Burger DM, la Porte CJ, and Koopmans PP: A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIVinfected adults. Ther Drug Monit 2006;28(5):650-653.
35. Guillemi SA, et al.: 2004, Lopinavir trough concentration remains consistent for adult patients regardless of age. Int Cong Drug Therapy HIV, Glasgow, UK, #P292.
36. Zhou XJ, Havlir DV, Richman DD, et al.: Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000;14(18):2869-2876.
37. Buillon-Pichault M, Jullien V, Piketty C, et al.: A population analysis of weight-based differences in lopinavir pharmacokinetics and possible consequences for protease inhibitornave and experienced patients. Antiviral Ther 2009;14(7): 923-929.
38. Smith DE, Jeganathan S, and Ray J: Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials 2006;7(1):34-38.
39. Nettles RE, Kieffer TL, Parsons T, et al.: Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006;42(8):1189-1196.
40. Patterson K, Napravnik S, Eron J, et al.: Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med 2007;8(6): 406-410.
41. Silverberg MJ, Leyden W, Horberg MA, et al.: Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007;167(7):684-691.
42. Kilaru KR, Kumar A, Sippy N, et al.: Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med 2006;7(2):99-104.
43. Bosch RJ, Bennett K, Collier AC, et al.: Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44(3):268-277.
44. Goodkin K, Shapshak P, Asthana D, et al.: Older age and plasma viral load in HIV-1 infection. AIDS 2004;18(Suppl 1): S87-S98.
45. Wutoh AK, Elekwachi O, Clarke-Tasker V, Daftary M, Powell NJ, and Campusano G: Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr 2003;33(Suppl 2):S106-S114.
46. Kalayjian RC, Spritzler J, Pu M, et al.: Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005;192(9):1577-1587.
47. Moore RD and Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44(3):441-446.
48. Nogueras M, Navarro G, Antón E, et al.: Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis 2006;6:159.
49. Grabar S, Kousignian I, Sobel A, et al.: Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004;18(15):2029-2038.
50. Wolbers M, Battegay M, Hirschel B, et al.: CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007;12(6):889-897.
51. Connick E, Lederman MM, Kotzin BL, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000; 181(1):358-363.
52. Viard JP, Mocroft A, Chiesi A, et al.: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. EuroSIDA Study Group. J Infect Dis 2001;183(8):1290-1294.
53. Smith CJ, Sabin CA, Youle MS, et al.: Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004;190(10):1860-1868.
54. de Wildt SN, Kearns GL, Leeder JS, and van den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
55. Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, and Jacqz-Aigrain E: Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005; 33(11):1603-1607.
56. Parkinson A, Mudra DR, Johnson C, Dwyer A, and Carroll KM: The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199(3):193-209.
57. Schwarz JB: The current state of knowledge on age, sex and their interactions on clinical pharmacology. Clin Pharm Ther 2007;82:87-96.
58. Cotreau MM, von Molte LL, and Greenblatt DJ: The influence of age and sex on the clearance of CYP450 3A substrates. Clin Pharmacokinet 2005;44:33-60.
59. Cummins C, Wu C-Y, and Benet L: Sex related differences in the clearance of cytochrome P450 3A4 substrates may be caused by p-glycoprotein. Clin Pharm Ther 2002;72:474-489.
60. Krecic-Shepard M, Park K, Barnas C, Slimko J, Kerwin D, and Schwartz J: Race and sex influence clearance of nifedipine: Results of a population study. Clin Pharmacol Ther 2000;68:130-142.
61. Kang D, Vercotta D, and Schwartz J: Population analyses of sustained-release verapamil in patients: Age, race and sex effects. Clin Pharm Ther 2003;73:31-40.
62. Kang D, Vercotta D, and Schwartz J: Population analyses of amlodipine in patients living in the community and in nursing homes. Clin Pharm Ther 2006;79:114-124.
63. Cvetkovic RS and Goa KL: Lopinavir=ritonavir: A review of its use in the management of HIV infection. Drugs 2003;63(8): 769-802.
64. Wynne H: Drug metabolism and ageing. J Br Menopause Soc 2005;11(2):51-56.
65. Zeeh J: The aging liver: Consequences for drug treatment in old age. Arch Gerontol Geriatr 2001;32(3):255-263.
66. Schmucker DL: Liver function and phase I drug metabolism in the elderly: A paradox. Drugs Aging 2001;18(11):837-851.
67. Plasschaert SL, Vellenga E, de Bont ES, et al.: High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma 2003;44(1):85-95.
68. Washington CB, Duran GE, Man MC, et al.: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(3):203-209.
69. Schön A, del Mar Ingaramo M, and Freire E: The binding of HIV-1 protease inhibitors to human serum proteins. Biophys Chem 2003;105(2-3):221-230.
70. Zhang XQ, Schooley RT, and Gerber JG: The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180(6):1833-1837.
71. Jones K, Hoggard PG, Khoo S, et al.: Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. Br J Clin Pharmacol 2001;51(1):99-110.
72. Boffito M, Hoggard PG, Lindup WE, et al.: Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004;26(1):35-39.
73. Woo J, Chan HS, Or KH, and Arumanayagam M: Effect of age and disease on two drug binding proteins: Albumin and alpha-1-acid glycoprotein. Clin Biochem 1994;27(4):289-292.
74. Mackiewicz A and Mackiewicz K: Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Glycoconj J 1995;12(3):241-247.
75. Mackiewicz A, Khan MA, Górny A, et al.: Glycoforms of alpha 1-acid glycoprotein in sera of human immunodeficiency virus-infected persons. Infect Dis 1994;169(6):1360-1363.
76. Klotz U: Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41(2):67-76.
77. Hilmer SN: ADME-tox issues for the elderly. Expert Opin Drug Metab Toxicol 2008;4(10):1321-1331.
78. Fabbiani M, DiGiambenedetto S, Ragazzoni E, and DeSimone A: Pharmacokinetic variability of darunavir and raltegravir in routine clinical practice. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, 2009, #P-11.
79. Von Hentig N, Stephen C, Nisius G, and Bickel M: Factors related to very high lopinavir plasma concentrations in an unselected outpatient cohort of HIV-infected adults. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, 2009, #P-43.